Caption Management 13F: Adds $5.1M to CG Oncology (CGON) Stake

Caption Management Expands Biotech Holdings

Caption Management boosted its holdings in CG Oncology, Inc. (NASDAQ: CGON) by 23.3% during the latest reporting period. The investment firm added 71,634 shares to its portfolio, bringing its total position to 378,480 shares. At the end of the quarter, the investment was valued at $26,891,005. This information comes from Caption Management's latest Form 13F filing with the Securities and Exchange Commission, which reflects portfolio holdings as of May 15, 2026, and may not represent the fund's current holdings.

Caption Management is known for its tactical, multi-strategy approach to investing, often taking positions in fast-moving sectors like biotechnology where clinical trial results can drive significant value. This recent addition suggests the firm is building on its conviction in CG Oncology's pipeline.

CG Oncology Stock Performance

On Sunday, CG Oncology stock traded at $71.05. The stock has shown solid momentum, trading significantly above its 200-day moving average of $62.63, though it remains slightly below its 50-day moving average of $74.13. Over the last year, the stock has moved between a low of $35.64 and a high of $80.97. The company's market capitalization currently sits at $6.94 billion.

Recent Earnings and Financial Health

For its most recent financial periods, CG Oncology reported revenue of $6,228,000. The company is not currently profitable, posting an earnings per share loss of $2.69, meaning it does not have a meaningful price-to-earnings ratio. However, the business maintains a highly liquid balance sheet, with a current ratio of 22.219 and a quick ratio of 21.776, indicating ample short-term funding to support its ongoing research operations. Its next earnings report is scheduled for November 9, 2026.

Insider Buying and Selling at CG Oncology, Inc.

Corporate insiders have also been active in the stock. On June 15, 2026, insider James Mulay engaged in two transactions. Mulay acquired 1,964 shares at an average price of $9.64 per share, representing a total value of $18,925.69. On that same day, Mulay also disposed of 1,964 shares.

Analysts Set New Price Targets

Wall Street research firms have recently reviewed their positions on the biotechnology firm. On August 7, 2026, RBC Capital maintained an Outperform rating on the stock and adjusted its price target to $79.00. Also on August 7, 2026, Piper Sandler maintained its Overweight rating and set an $85.00 price target. Truist Securities followed suit on August 7, 2026, keeping a Buy rating and establishing an $85.00 price target. Overall, the stock carries a strong buy consensus rating from 13 analyst opinions, with an average price target of $91.08.

About CG Oncology

CG Oncology is a clinical-stage biopharmaceutical firm that focuses on developing and commercializing immunotherapies for bladder cancer patients. The company's lead investigational drug, cretostimogene, is currently undergoing multiple advanced Phase 2 and Phase 3 clinical trials, targeting high-risk and intermediate-risk bladder cancer cases that have failed traditional therapies.

What's Ahead for CG Oncology, Inc.

Investors tracking CG Oncology will want to keep a close eye on the upcoming November 9, 2026, earnings announcement for updates on its lead clinical trials. While quarterly 13F filings provide a helpful backward-looking window into where institutional money is moving, they do not guarantee that Caption Management or any other investment firm still holds these exact positions today.